Skip to content
Triangle logo TriangleGet started
← Study library

NCT00577278 · REGISTRY CONDITION SEARCH

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2024-02-16

RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor that do not exactly match the patient's blood, are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and sirolimus before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects and how well giving indium In 111 ibritumomab tiuxetan and yttrium y 90 ibritumomab tiuxetan together with rituximab, fludarabine, melphalan, and donor stem cell transplant works in treating patients with B-cell non-Hodgkin lymphoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Relapse/Progression Rate at Two Years

→

outcome · POSTED

Overall Survival at Two Years

→

outcome · POSTED

Progression-free Survival at Two Years

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * 6/6/human leukocyte antigen (HLA) matched sibling donor or related donor, or acceptable matched unrelated donor * Biopsy (Bx) proven diagnosis of LG (including small lymphocytic lymphoma \[SLL\]/chronic lymphocytic leukemia \[CLL\], lymphoplasmacytic lymphoma, marginal zone, mucosa-associated lymphoid tissue \[MALT\] lymphoma and follicular lymphoma \[FL\] grade 1 and 2), IG (FL grade 3 and DLCL) or MCL NHL * Prior demonstrated monoclonal CD20+ malignant B-Cell population in lymph nodes and/or BM Bx specimen * LG NHL; must have relapsed after achieving a complete response (CR) or partial response (PR) to prior therapy or have never responded to prior therapy, including chemotherapy and/or MAb therapy * MCL NHL in any disease state * Other aggressive B-cell lymphomas (excluding Burkitt lymphoma or Burkitt-like lymphoma) having had at least one relapse or having been refractory to chemotherapy * Bone marrow (BM) aspiration and Bx ( =\< 42 days prior to imaging dose) which show \< 25% lymphomatous involvement of total cellularity; in CLL, peripheral lymphocyte count \< 5000/mm\^3 * Salvage chemotherapy/MAbs to reduce BM lymphomatous involvement and reduce disease bulk allowed * Normal renal function test with serum creatinine of =\< 1.5 mg/dl, or a creatinine clearance of \>= 60 ml/min * Adequate pulmonary function as measured by forced expiratory volume in one second (FEV1) \> 65% of predicted measured, or a diffusing capacity of carbon monoxide (DLCO) \>= 50% of predicted measured * Cardiac Ejection fraction of \> 50% by Echocardiogram (ECHO) or multi gated acquisition (MUGA) * Adequate liver function tests with a bilirubin of =\< 1.5 x normal and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) =\< 2 x normal * Negative Human Immunodeficiency Virus (HIV) antibody * Karnofsky Performance Status (KPS) \> 80 * No active Central Nervous System (CNS) disease or prior history of CNS disease * Involved field External Beam Therapy (EBT) to area excluding lung, heat, liver, and kidney allowed, but evaluated on a case-by-case basis * Recovery from last therapy and therapy dose (Y-90 Zevalin) must be \>= 4 weeks from prior systemic chemotherapy * DONOR: Age \< 75 years * DONOR: HLA genotypically identical related donor or acceptable matched unrelated donor * DONOR: Must consent to G-CSF administration and leukapheresis for matched sibling donor, but for unrelated donor, the donor will sign a standard consent for donation at their designated donor or collection center * DONOR: Must have adequate veins for leukapheresis or agree to placement of a Central Venous Catheter (CVC \[femoral, subclavian\]) Exclusion Criteria: * Presence of Human Anti-Zevalin Antibody (HAZA) * Prior radioimmunotherapy (RIT) * Prior AHSCT; but prior aHSCT is allowed; prior fractionated total body irradiation (FTBI) in the conditioning regimen will be evaluated on an individual basis * Prior malignancy, except for: adequately treated basal cell or squamous cell skin cancer; adequately treated noninvasive carcinomas; or other cancer from which the patient has been disease-free for at least 5 years; myelodysplastic syndromes (MDS) is excluded from this criterion * Active evidence of Hepatitis B or C infection; hepatitis B surface antigen positive * Total peripheral lymphocyte count \> 5,000/mm\^3 if SLL/CLL * Burkitt lymphoma or Burkitt-like lymphoma * DONOR: Age \< 12 years * DONOR: Identical twin * DONOR: Pregnancy * DONOR: HIV infection * DONOR: Inability to achieve adequate venous access * DONOR: Known allergy to G-CSF * DONOR: Current serious systemic illness or any disease that may preclude the use of G-CSF (eg, recent thromboembolic event); for unrelated donors, considered ineligible by National Marrow Donor Program (NMDP) donor evaluation center
healthy Volunteers
false
maximum Age
69 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
    intervention Names
    1. Biological: rituximab
    2. Drug: fludarabine phosphate
    3. Drug: melphalan
    4. Drug: sirolimus
    5. Drug: tacrolimus
    6. Procedure: allogeneic hematopoietic stem cell transplantation
    7. Radiation: indium In 111 ibritumomab tiuxetan
    8. Radiation: yttrium Y 90 ibritumomab tiuxetan
    9. Other: laboratory biomarker analysis
    label
    Treatment (chemo, monoclonal antibody therapy, transplant)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Given IV
    name
    rituximab
    other Names
    1. IDEC-C2B8
    2. IDEC-C2B8 monoclonal antibody
    3. Mabthera
    4. MOAB IDEC-C2B8
    5. Rituxan
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Given IV
    name
    fludarabine phosphate
    other Names
    1. 2-F-ara-AMP
    2. Beneflur
    3. Fludara
    type
    DRUG
  3. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Given IV
    name
    melphalan
    other Names
    1. Alkeran
    2. CB-3025
    3. L-PAM
    4. L-phenylalanine mustard
    5. L-Sarcolysin
    type
    DRUG
  4. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Given PO
    name
    sirolimus
    other Names
    1. AY 22989
    2. Rapamune
    3. rapamycin
    4. SLM
    type
    DRUG
  5. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Given PO or IV
    name
    tacrolimus
    other Names
    1. FK 506
    2. Prograf
    type
    DRUG
  6. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Undergo APBSCT
    name
    allogeneic hematopoietic stem cell transplantation
    type
    PROCEDURE
  7. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Given IV
    name
    indium In 111 ibritumomab tiuxetan
    other Names
    1. IDEC-In2B8
    type
    RADIATION
  8. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Given IV
    name
    yttrium Y 90 ibritumomab tiuxetan
    other Names
    1. 90Y ibritumomab tiuxetan
    2. IDEC Y2B8
    3. Y90 Zevalin
    4. Y90-labeled ibritumomab tiuxetan
    type
    RADIATION
  9. arm Group Labels
    1. Treatment (chemo, monoclonal antibody therapy, transplant)
    description
    Correlative Studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
41
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    The primary endpoint was 2-year cumulative incidence of relapse/progression (RP), defined as time from alloHCT to disease recurrence or progression. Cumulative incidences for RP was generated in a competing-risk setting, given that death events were competing events.
    measure
    Relapse/Progression Rate at Two Years
    time Frame
    From the initial treatment to the last disease assessment, up to two years
secondary Outcomes
  1. description
    Overall survival (OS) was measured from initial treatment to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.
    measure
    Overall Survival at Two Years
    time Frame
    From the initial treatment to the last disease assessment, up to two years
  2. description
    Progression-free survival (PFS) was measured from initial treatment to disease progression or death from any cause, whichever came first. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.
    measure
    Progression-free Survival at Two Years
    time Frame
    From the initial treatment to the last disease assessment, up to two years
Full study description
brief Summary
RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor that do not exactly match the patient's blood, are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and sirolimus before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects and how well giving indium In 111 ibritumomab tiuxetan and yttrium y 90 ibritumomab tiuxetan together with rituximab, fludarabine, melphalan, and donor stem cell transplant works in treating patients with B-cell non-Hodgkin lymphoma.
detailed Description
PRIMARY OBJECTIVES: I. To evaluate the safety and efficacy of a preparative regimen of Yttrium-90 (90\^Y)- labeled anti-cluster of differentiation (CD)20 monoclonal antibody (MAb) (yttrium Y 90 ibritumomab tiuxetan) in combination with fludarabine (fludarabine phosphate) and melphalan followed by allogeneic hematopoietic stem cell transplant (APBSCT) for treatment of patients with B-cell low-grade non-Hodgkin lymphoma (LG NHL), intermediate-grade non-Hodgkin lymphoma (IG NHL) and mantle cell lymphoma (MCL). II. To evaluate the short- and long-term complications of this new preparative regimen, including rates of engraftment, acute and chronic graft-versus-host-disease (GVHD) and infectious complications. III. To estimate the disease response rate, disease relapse (progression) rate, and non-relapse mortality rate. IV. To perform exploratory studies that seek to measure/characterize the expression of costimulatory molecules and impact of these molecules on the natural killer (NK) and T cells of a subset of lymphoma patients pre- post- allogeneic stem cell transplant (ASCT) and the stem cell product from a portion of sibling donors. OUTLINE: REDUCED-INTENSITY CONDITIONING: Patients receive rituximab intravenously (IV) followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or orally (PO) and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper. After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for up to 5 years.
Source references
references
  1. citation
    Mei M, Palmer J, Tsai NN, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai JL, Htut M, Nakamura R, Al Malki MM, Herrera A, Wong J, Nademanee A. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e268-e276. doi: 10.1016/j.clml.2023.05.011. Epub 2023 May 23.
    pmid
    37301631
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-f6ab73855e23ca9fb58e
      requested nct id
      NCT00577278
      primary nct id
      NCT00577278
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      7e148fe92ffbe3ff46223b586d291f2f8bb05d61b6b1bda3984c0acb1e0ea1eb
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-f6ab73855e23ca9fb58e
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00577278
      occurrences
      1. context exact
        NCT00577278
        end
        11
        exact text
        NCT00577278
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/904/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      59df6d47dcb9acc3a34b28688c7d53cf53c4646b21293ddbe34b0a3e83c2333f

    Preserved source evidence · Not medical advice